Business Daily Media

The Times Real Estate

.

HKU AIDS Institute & Immuno Cure’s Collaborative Therapeutic HIV Vaccine Research Project secured HK$66.7m TRS funding from Research Grant Council

Research Funding for Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions

HONG KONG SAR - Media OutReach Newswire - 18 July 2024 - Immuno Cure BioTech ("Immuno Cure") is pleased to announce today that a collaborative research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions" ("Project") led by Prof.

Zhiwei Chen of The University of Hong Kong ("HKU") on our therapeutic HIV vaccine ("ICVAX") has been awarded HK$66.7 million of funding under the Theme-based Research Scheme ("TRS") of the Research Grants Council ("RGC") for a second 5-year term.

HIV/AIDS are a global health concern, especially significant in Hong Kong. Based on Centre for Health Protection's record, a cumulative total of 12,143 cases of HIV infection and 2,507 cases of AIDS are found in Hong Kong, which have been steadily increasing over the years. The current combination antiretroviral therapy ("cART") target suppressing viral reproduction while this project will further investigate the effect of using our PD-1-enhanced DNA vaccine technologies on immunogenicity.

The Project is led by Professor Zhiwei Chen, Director of the AIDS Institute and Chair Professor of the Department of Microbiology, School of Clinical Medicine, LKS Faculty of Medicine of HKU, and the Principal Scientific Advisor of Immuno Cure. The research will be performed in collaboration with Immuno Cure, Chinese University of Hong Kong Phase 1 Clinical Trial Centre, The Third People's Hospital of Shenzhen, and other hospitals in the Mainland where the collaborative team of researchers will investigate and determine the mechanism of PD-1-based DNA vaccine-mediated 7-year cART-free virologic control in SHIV-infected rhesus monkeys; the impact of PD-1-base DNA vaccine on cART-treated people living with HIV-1 ("PLWH"); and the sustained cART-free HIV-1 control using analytical treatment interruption ("ATI") and combinational immunotherapy.

Immuno Cure will contribute to the manufacturing of ICVAX and the design and management of the clinical trials with our aim to determine the ATI amongst the PLWH of ICVAX Phase 1 Trial; to optimise the immunogenicity of ICVAX by conducting a multi-centre Phase 2 Trial; and to determine the immunotherapeutic efficacy by combining ICVAX with other complementary strategies. This Project will strengthen Hong Kong Research Consortium on HIV/AIDS in collaboration with international experts and scientific advisors, and also reveal mechanisms underlying a promising "Made in Hong Kong" immunotherapy in clinical trials. It will ultimately contribute to the understanding of long-term viral control and potential alternative treatment strategies for HIV-1 without cART treatment in future.

Prof. Zhiwei CHEN, Director of AIDS Institute of HKU and the Principal Scientific Advisor of Immuno Cure, said "Preliminary Phase 1 Trial data demonstrated that the HKU patented PD-1-enhanced DNA vaccine ICVAX has shown convincing safety and immunogenicity profiles in PLWH. Our team members are very grateful that this TRS grant will allow us to expand our translational research to benefit more and more PLWH."

Dr. Xia JIN, CEO of Immuno Cure & Co-PI of the Project, said, "We are excited to be a key member of the collaborative research team led by Prof. Chen, with whom we have many years of close working relationship. This TRS-funded research will enhance our understanding of the mechanisms of the immune protection and enable us to further investigate the potential of ICVAX towards functional cure of HIV/AIDS."

Dr. Percy CHENG, Chairman of Immuno Cure, concluded, "Immuno Cure is delighted to have earned RGC's support and recognition of our ICVAX research which is of strategic importance to Hong Kong's long-term development. This milestone allows us to carry out academic collaborative research with HKU's AIDS Institute and other top ranked universities in Hong Kong and the Mainland for the advancement of our combat against HIV/AIDS. We are also grateful for the involvement of all the global expert advisors organised by Prof. Chen."

Hashtag: #ImmunoCure #HKU #AIDS

The issuer is solely responsible for the content of this announcement.

About Immuno Cure

Immuno Cure is a clinical stage biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine and Anti-Δ42PD1 Antibody platforms; with two DNA vaccine candidates currently in clinical trials.

To learn more about Immuno Cure, please visit:

About The University of Hong Kong and AIDS Institute of HKUMed

The University of Hong Kong (HKU), founded in 1911, is the first and oldest institution of higher learning in Hong Kong. HKU has an established worldwide reputation for being a research-led comprehensive university. The AIDS Institute of HKU was established in November 2007 to take HKU in a new strategic direction in fighting this global epidemic and help to make it a leader in the region in AIDS research, education and prevention. Scientists at the AIDS Institute are fully committed to conducting basic and applied research that facilitates the understanding of AIDS pathogenesis and the development of effective AIDS vaccines. Furtherance to the Hong Kong Theme-based Research Scheme entitled "Potentiating Host Immunity for HIV-1 Functional Cure", the institute is currently leading the second 5-year term research entitled "Sustained cART-free HIV-1 Control by Immunotherapeutic Interventions".

To learn more about HKU and AIDS Institute of HKU, please visit and

About Research Grant Council and Theme-based Research Scheme

To learn more about RGC, please visit:

To learn more about TRS, please visit:

News from Asia

LFC and adidas reunite with new multi-year partnership

LIVERPOOL, UK - Media OutReach Newswire - 13 March 2025 - Liverpool Football Club and adidas have agreed a new multi-year partnership that will see the sportswear giant once again become the club...

Prince Holding Group Earns Fifth Consecutive ‘Best in Cambodia’ Award for CSR Initiatives

Recognized at the 17th Annual Global CSR & ESG Awards for Sustainable Development Efforts PHNOM PENH, CAMBODIA - Media OutReach Newswire - 13 March 2025 - Prince Holding Group has been recogni...

Galaxy Macau’s Reveals a Galaxy of Stars As the Integrated Resort’s Restaurants are Awarded Five Michelin Stars in the 17th Michelin Guide Hong Kong Macau 2025

Sushi Kissho by Miyakawa Celebrates a Stellar Debut MACAU SAR - Media OutReach Newswire - 13 March 2025 - In the 17th Michelin Guide Hong Kong Macau 2025, Galaxy Macau™, the world-class luxury in...

Melco continues to lead with the city’s top number of Stars granted by MICHELIN Guide Hong Kong & Macau 2025

MACAO SAR - Media OutReach Newswire - 13 March 2025 - Melco Resorts & Entertainment continues to lead in Macau in the newly published MICHELIN Guide Hong Kong & Macau 2025, being granted ...

Singapore G Unveils the Largest Cold Storage Facility in Central Singapore, Reinforcing Its Commitment to Supporting SMEs and Business Growth

SINGAPORE - Media OutReach Newswire - 14 March 2025 - Singapore G, a trailblazer in space solutions, today announced the grand opening of MustardSeed@SG Cold Store, a cold storage facility in the ...

GROW with Singlife and aberdeen Launch New Exclusive Share Class of Global Income Bond Fund to Deliver Sustainable Payouts Amid Market Volatility

Globally diversified portfolio of crossover bonds aims to deliver attractive yields for investors SINGAPORE - Media OutReach Newswire - 14 March 2025 - GROW with Singlife ("GROW"), the integrated...

Konica Minolta wins 2025 A3 Line of the Year Award and four Pick Awards from Keypoint Intelligence

Recognition of Konica Minolta’s adaptable, future-ready innovations in office printing technology. SINGAPORE - Media OutReach Newswire - 14 March 2025 – Konica Minolta has been awarded five ...

Silver vs. Gold: Octa Broker's Expert Take on the Future of Precious Metals

KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 14 March 2025 - Silver is attracting investor interest, with market analysts predicting a potential leap to $40 per troy ounce in 2025...

Asia trade set for continued growth despite challenging global business environment, reveals DHL Trade Atlas 2025

India, Vietnam, Indonesia, and the Philippines are forecast to lead in both speed and scale of trade growth from 2024 to 2029 South Asia and Southeast Asia regions set to ach...

Incode joins Australia’s Age Assurance Technology Trial to protect children online

With a market-leading +99% accuracy rate, Incode will play a key role in safeguarding Aussie minors on social media Incode Technologies Inc., a...

Empowering small businesses: Localsearch rolls out affordable digital solutions

New suite of digital solutions designed to boost visibility, engagement, and customer acquisition In response to a rapidly evolving digital lan...

Why Responsible Leadership is a Competitive Advantage for Small Businesses

In today’s fast-changing business landscape, leadership is evolving. While large corporations are reassessing their diversity, equity, and inclusi...

Why it’s a great time to include the EU in your export push

With the US market beset with unknowns, training your sights on mainland Europe in 2025 makes sound sense. Wondering whether the introduction o...

Success Isn’t About Labels—It’s About Mindset

In the lead up to International Women’s Day, I’ve been reflecting on my own success as a business owner and whether or not being a woman has playe...

Accelerate Action- Thryv champions women in business for International Women’s Day

Thryv® (NASDAQ: THRY), provider of the leading small business software platform, is celebrating International Women’s Day by shining a spotlight o...

Sell by LayBy